Invuity touts data from device-assisted mastectomy study

Invuity (NSDQ:IVTY) said today that data from a retrospective analysis of its Eikon illuminated retractor system during nipple-sparing mastectomies showed positive economic and clinical benefits.

Data from the study indicated a reduction in anasthesia time of 31 minutes, or 10%, a reduction in overall complication rates, a 70% reduction in epidermolysis and potential savings between $580 a $2,000, according to the San Francisco, Calif.-based company.

“We are pleased with these positive results, which show there are tangible and significant benefits to both patients and hospitals from the use of our Intelligent Photonics technology during advanced surgical procedures,” CEO Philip Sawyer said in a press release.

The review is the 1st in a series of analysis planned to determine if intracavity illumination and visualization can improve patient outcomes and reduce time and costs associated with the procedure, Invuity said.

“Nipple sparing mastectomies have become a desirable option for the oncologic treatment of breast cancer with excellent clinical and aesthetic outcomes shown in appropriate patients. Based on the positive outcomes of this analysis, we plan to conduct continued research to further confirm the benefit of advanced access and visualization technologies in enabling this innovative approach to breast cancer surgery,” Dr. Beth DuPree said in a prepared statement.

“We look forward to continuing our research. Whenever possible, before surgery, patients should partner with their care team to learn about the breast reconstruction options available to them. Having advanced access and visualization tools from the beginning not only helps reduce surgical time and complications, but enables us to give patients aesthetic results that can help boost their psychological and emotional recovery,” Dr William Scarlett said in prepared remarks.

In June, Invuity said it closed its initial public offering, raising approximately $47.8 million by offering 4.6 million shares at $12 per share.

The IPO’s underwriters exercised a 600,000-share over-allotment, the San Francisco, Calif.-based surgical illumination device company said.  Invuity’s stock is listed under the IVTY symbol on the NASDAQ exchange, and began trading on June 15.

When the offering was filed in April, Invuity said it hoped to raise $69 million, estimating the market potential for its products at $2 billion. In June, the company lowered the price range to $14 to $16, which at the midpoint would have raised $60 million. Invuity raised a $36 million Series E round in March 2014.

The post Invuity touts data from device-assisted mastectomy study appeared first on MassDevice.

from MassDevice http://ift.tt/1ODsU2T